

Special Issue

Current Treatments of Esophageal and Esophagogastric Junction Cancers

Message from the Guest Editor

Esophageal and esophagogastric junction cancers have high morbidity and mortality rates worldwide. In the past, various therapies have been attempted in these cancers but returned unsatisfactory results. Recently, however, treatment outcomes have improved remarkably through the development of endoscopic treatment for early-stage cancer; minimally invasive and sophisticated surgical procedures including thoracoscopic and robot-assisted surgery; and advances in chemotherapy and chemoradiotherapy for advanced cancer. The emergence of immune checkpoint inhibitors has also led to remarkable improvements in the treatment of advanced cancers. In this Special Issue, we would like to introduce the latest treatment methods for esophageal cancer and esophagogastric junction cancer and to disseminate knowledge on their results and future issues.

Guest Editor

Dr. Masanobu Nakajima

Department of Upper Gastrointestinal Surgery, Dokkyo Medical University, Tochigi, Japan

Deadline for manuscript submissions

closed (31 August 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/219218

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)